Junru Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Junru Liu has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Juan Li
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
7 shared publications Beihui Huang
Department of Hematology The First Affiliated Hospital of Sun Yat‐Sen University Guangzhou Guangdong China
3 shared publications- Beihui Huang
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
3 shared publications - Jingli Gu
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
3 shared publications Lifen Kuang
Department of Hematology The First Affiliated Hospital of Sun Yat‐Sen University Guangzhou Guangdong China
3 shared publicationsMeilan Chen
Department of Hematology The First Affiliated Hospital of Sun Yat‐Sen University Guangzhou Guangdong China
3 shared publications
Latest Publications
- Open Access
The Prognostic Significance of Dynamic Monitoring of Minimal Residual Disease Status in Patients with Multiple Myeloma: A Real-World Study
Background: Minimal residual disease (MRD) is an established prognostic factor in multiple myeloma (MM), but the significance of dynamic MRD changes before and after autologous stem cell transplantation (ASCT) remains unclear. Methods: We retrospectively analysed 335 newly diagnosed MM patients who underwent upfront ASCT. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence interval (CI), adjusting for clinical risk factors. Results: Patients were classified as having persistent MRD negativity (n = 82, 24.5%), MRD− to MRD+ conversion (n = 40, 11.9%), MRD+ to MRD− conversion (n = 168, 50.1%), or persistent MRD positivity (n = 45, 13.4%). Median OS was not reached: 105, 131, and 87 months for the groups (p < 0.001); and PFS was not reached: 50, 71, and 38 months (p < 0.001). In multivariable analysis, persistent MRD positivity (HR, 4.762; 95% CI, 2.151–10.546; p < 0.001) and MRD− to MRD+ conversion (HR, 3.925; 95% CI, 1.791–8.598; p < 0.001) were associated with increased mortality risk compared with persistent MRD negativity, whereas MRD+ to MRD− conversion showed a borderline-significant increase (HR, 1.973; 95% CI, 0.963–4.046; p = 0.063). In addition, similar patterns were observed for PFS. In subgroup analyses, late MRD+ to MRD− conversion was associated with inferior PFS (HR, 1.857; 95% CI, 1.136–3.034; p = 0.014), whereas MRD− to MRD+ conversion showed no differences in OS or PFS (all p > 0.05). Among persistent MRD-positive patients, stable or increasing MRD pattern predicted worse outcomes (HR, 4.397; 95% CI, 1.190–16.240; p = 0.026). Conclusions: Longitudinal MRD trajectories provided independent prognostic information beyond static MRD assessment in MM. Subgroup analyses further suggest that dynamic MRD assessment might help refine risk stratification after ASCT.
Open AccessThe Prognostic Significance of Dynamic Monitoring of Minimal Residual Disease Status in Patients with Multiple Myeloma: A Real-World Study
Background: Minimal residual disease (MRD) is an established prognostic factor in multiple myeloma (MM), but the significance of dynamic MRD changes before and after autologous stem cell transplantation (ASCT) remains unclear. Methods: We retrospectively analysed 335 newly diagnosed MM patients who underwent upfront ASCT. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence interval (CI), adjusting for clinical risk factors. Results: Patients were classified as having persistent MRD negativity (n = 82, 24.5%), MRD− to MRD+ conversion (n = 40, 11.9%), MRD+ to MRD− conversion (n = 168, 50.1%), or persistent MRD positivity (n = 45, 13.4%). Median OS was not reached: 105, 131, and 87 months for the groups (p < 0.001); and PFS was not reached: 50, 71, and 38 months (p < 0.001). In multivariable analysis, persistent MRD positivity (HR, 4.762; 95% CI, 2.151–10.546; p < 0.001) and MRD− to MRD+ conversion (HR, 3.925; 95% CI, 1.791–8.598; p < 0.001) were associated with increased mortality risk compared with persistent MRD negativity, whereas MRD+ to MRD− conversion showed a borderline-significant increase (HR, 1.973; 95% CI, 0.963–4.046; p = 0.063). In addition, similar patterns were observed for PFS. In subgroup analyses, late MRD+ to MRD− conversion was associated with inferior PFS (HR, 1.857; 95% CI, 1.136–3.034; p = 0.014), whereas MRD− to MRD+ conversion showed no differences in OS or PFS (all p > 0.05). Among persistent MRD-positive patients, stable or increasing MRD pattern predicted worse outcomes (HR, 4.397; 95% CI, 1.190–16.240; p = 0.026). Conclusions: Longitudinal MRD trajectories provided independent prognostic information beyond static MRD assessment in MM. Subgroup analyses further suggest that dynamic MRD assessment might help refine risk stratification after ASCT.
- Open Access
- 10 May 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71911
Outcomes Among MM Patients Receiving Early Intervention for MRD Progression Following Autologous Stem Cell Transplantation
Minimal residual disease (MRD) testing is essential for evaluating treatment response among multiple myeloma (MM) patients. Many patients experience MRD progression (MRD‐P) before they meet the criteria for clinical or biochemical progression (PD), thus raising questions about the timing of treatment. In this retrospective study, the effect of early intervention (EI) on prognosis was investigated among 42 newly diagnosed MM patients who developed MRD‐P after initial treatment with autologous stem cell transplantation. In the EI group ( n = 9), treatment was modified at the onset of MRD‐P; in the PD group ( n = 33), treatment was delayed until disease progression occurred. At a median follow‐up of 25 months, compared with the PD group, the EI group demonstrated a longer time to progression (median 34.8 months vs. 6.6 months, p = 0.029), superior overall survival (median not reached vs. 41.0 months, p = 0.034), and significantly higher MRD re‐negativity rates (median 12.6 months vs. 75.9 months, p < 0.001). Multivariate analysis revealed that early intervention was significantly associated with improved MRD re‐negativity (HR = 0.07; p = 0.001). This hypothesis‐generating retrospective study demonstrated that early intervention at MRD‐P onset was associated with improved survival outcomes and higher rates of MRD re‐negativity in this cohort. Despite significant limitations, such as the small sample size, nonrandomized design, and unmeasured confounders, these findings provide preliminary data to inform the design of future prospective randomized trials.
- 10 May 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71911
Open AccessOutcomes Among MM Patients Receiving Early Intervention for MRD Progression Following Autologous Stem Cell Transplantation
Minimal residual disease (MRD) testing is essential for evaluating treatment response among multiple myeloma (MM) patients. Many patients experience MRD progression (MRD‐P) before they meet the criteria for clinical or biochemical progression (PD), thus raising questions about the timing of treatment. In this retrospective study, the effect of early intervention (EI) on prognosis was investigated among 42 newly diagnosed MM patients who developed MRD‐P after initial treatment with autologous stem cell transplantation. In the EI group ( n = 9), treatment was modified at the onset of MRD‐P; in the PD group ( n = 33), treatment was delayed until disease progression occurred. At a median follow‐up of 25 months, compared with the PD group, the EI group demonstrated a longer time to progression (median 34.8 months vs. 6.6 months, p = 0.029), superior overall survival (median not reached vs. 41.0 months, p = 0.034), and significantly higher MRD re‐negativity rates (median 12.6 months vs. 75.9 months, p < 0.001). Multivariate analysis revealed that early intervention was significantly associated with improved MRD re‐negativity (HR = 0.07; p = 0.001). This hypothesis‐generating retrospective study demonstrated that early intervention at MRD‐P onset was associated with improved survival outcomes and higher rates of MRD re‐negativity in this cohort. Despite significant limitations, such as the small sample size, nonrandomized design, and unmeasured confounders, these findings provide preliminary data to inform the design of future prospective randomized trials.
- Open Access
- 3 November 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2579793
Impact of early minimal residual disease assessment on the outcomes of patients with systemic light chain amyloidosis
Systemic light chain (AL) amyloidosis is associated with a high mortality rate, particularly in the first year after diagnosis. Minimal residual disease (MRD) assessment plays a key role in the prognosis of AL amyloidosis but is typically performed later in the treatment process, thereby limiting its ability to guide early interventions. This retrospective study included 53 newly diagnosed AL amyloidosis patients who underwent MRD assessment via flow cytometry after two chemotherapy cycles. The aim of this study was to assess the effect of early MRD negativity on organ response kinetics and prognosis. After two chemotherapy cycles, 22.6% (12/53) of patients achieved early MRD negativity. Daratumumab-treated patients had a significantly greater early MRD negativity rate (41.46%/0%, p = 0.019). Early MRD-negative patients had a significantly longer event-free survival (EFS) (not reached vs. 37.48 months, p = 0.029) than MRD-positive patients. In terms of organ response, early MRD-negative patients with cardiac or renal involvement had higher complete response (CR) rates and significantly shorter times to cardiac and renal CR (cardiac CR = 5.6 months vs. 28.4 months, p = 0.009; renal CR = 12.2 months vs. 41.0 months; p < 0.001). Early MRD negativity predicts faster/deeper organ responses in AL amyloidosis patients and is associated with improved prognosis. These findings offer new possibilities for integrating early MRD assessment into clinical practice.
- 3 November 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2579793
Open AccessImpact of early minimal residual disease assessment on the outcomes of patients with systemic light chain amyloidosis
Systemic light chain (AL) amyloidosis is associated with a high mortality rate, particularly in the first year after diagnosis. Minimal residual disease (MRD) assessment plays a key role in the prognosis of AL amyloidosis but is typically performed later in the treatment process, thereby limiting its ability to guide early interventions. This retrospective study included 53 newly diagnosed AL amyloidosis patients who underwent MRD assessment via flow cytometry after two chemotherapy cycles. The aim of this study was to assess the effect of early MRD negativity on organ response kinetics and prognosis. After two chemotherapy cycles, 22.6% (12/53) of patients achieved early MRD negativity. Daratumumab-treated patients had a significantly greater early MRD negativity rate (41.46%/0%, p = 0.019). Early MRD-negative patients had a significantly longer event-free survival (EFS) (not reached vs. 37.48 months, p = 0.029) than MRD-positive patients. In terms of organ response, early MRD-negative patients with cardiac or renal involvement had higher complete response (CR) rates and significantly shorter times to cardiac and renal CR (cardiac CR = 5.6 months vs. 28.4 months, p = 0.009; renal CR = 12.2 months vs. 41.0 months; p < 0.001). Early MRD negativity predicts faster/deeper organ responses in AL amyloidosis patients and is associated with improved prognosis. These findings offer new possibilities for integrating early MRD assessment into clinical practice.
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1)
MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma
Real-world studies have shown that Mayo Additive Staging System (MASS) −3 and MASS-4 are suitable for prognostic stratification in Chinese patients with newly diagnosed multiple myeloma (NDMM), but there is no clear evidence of their utility in transplant-eligible NDMM patients. We aimed to evaluate and compare the prognostic stratification value of MASS-3 and MASS-4 in transplant-eligible patients with NDMM in China. A retrospective analysis of the clinical data of 215 NDMM patients who received ‘induction therapy-autologous hematopoietic stem cell transplantation (ASCT)’ in our center from 2013 to 2022 was performed. The prognostic stratification value of the two staging techniques was compared in terms of patient’s overall survival (OS) and progression free survival (PFS), using different transplant times, different ages, and different induction regimens. The median progression-free survival (PFS) was 99, 88, and 51 months (p = 0.010), and the median overall survival (OS) was not reached, 110, and 80 months (p = 0.003) in MASS-3 I, II, and III patients, respectively. The median PFS was 99, 88, 53, and 35 months (p = 0. 002), and the median OS was not reached, 110, 106, and 41 months (p < 0.001) for patients in MASS-4 I, II, III, and IV, respectively. And MASS-4 can identify patients with poor prognosis among the Revised International Staging System (R-ISS) stage II patients. In patients with single ASCT, different ages, and different induction regimens, the prognostic stratification of MASS-4 was also better than that of MASS-3. However, there was no significant difference in PFS and OS between different MASS-3 or MASS-4 stages in patients with tandem ASCT. Among transplant-eligible patients with NDMM, the prognostic stratification value of MASS-4 was better than that of MASS-3, particularly distinguishing high-risk patients with poor prognosis. Compared with single ASCT, tandem ASCT may overcome the poor prognosis of high-risk MASS patients.
- 1 July 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1)
Open AccessMASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma
Real-world studies have shown that Mayo Additive Staging System (MASS) −3 and MASS-4 are suitable for prognostic stratification in Chinese patients with newly diagnosed multiple myeloma (NDMM), but there is no clear evidence of their utility in transplant-eligible NDMM patients. We aimed to evaluate and compare the prognostic stratification value of MASS-3 and MASS-4 in transplant-eligible patients with NDMM in China. A retrospective analysis of the clinical data of 215 NDMM patients who received ‘induction therapy-autologous hematopoietic stem cell transplantation (ASCT)’ in our center from 2013 to 2022 was performed. The prognostic stratification value of the two staging techniques was compared in terms of patient’s overall survival (OS) and progression free survival (PFS), using different transplant times, different ages, and different induction regimens. The median progression-free survival (PFS) was 99, 88, and 51 months (p = 0.010), and the median overall survival (OS) was not reached, 110, and 80 months (p = 0.003) in MASS-3 I, II, and III patients, respectively. The median PFS was 99, 88, 53, and 35 months (p = 0. 002), and the median OS was not reached, 110, 106, and 41 months (p < 0.001) for patients in MASS-4 I, II, III, and IV, respectively. And MASS-4 can identify patients with poor prognosis among the Revised International Staging System (R-ISS) stage II patients. In patients with single ASCT, different ages, and different induction regimens, the prognostic stratification of MASS-4 was also better than that of MASS-3. However, there was no significant difference in PFS and OS between different MASS-3 or MASS-4 stages in patients with tandem ASCT. Among transplant-eligible patients with NDMM, the prognostic stratification value of MASS-4 was better than that of MASS-3, particularly distinguishing high-risk patients with poor prognosis. Compared with single ASCT, tandem ASCT may overcome the poor prognosis of high-risk MASS patients.
- Open Access
- 9 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 145
Early Identification of the Non-Transplanted Functional High-Risk Multiple Myeloma: Insights from a Predictive Nomogram
Background: Patients with multiple myeloma (MM) who have a suboptimal response to induction therapy or early relapse are classified as functional high-risk (FHR) patients and have been shown to have a dismal prognosis. The aim of this study was to establish a predictive nomogram for patients with non-transplanted FHR MM. Materials and Methods: The group comprised 215 patients in our center between 1 January 2006 and 1 March 2024. To identify independent risk factors, univariate and multivariate logistic regression analyses were performed, and a nomogram was constructed to predict non-transplant FHR MM. To evaluate the nomogram’s predictive accuracy, we utilized bias-corrected AUC, calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC). Results: Multivariate logistic regression demonstrated that younger age at onset, a higher proportion of LDH (more than 220 U/L), pattern A + C of M protein decline patterns, a lower proportion of patients with induction treatment efficacy than VGPR, and those undergoing maintenance therapies were independent risk factors for patients with non-transplanted FHR MM. The AUC scores for the training and internal validation groups were 0.940 (95% CI 0.893–0.986) and 0.978 (95% CI 0.930–1.000). DCA and CIC curves were utilized to further verify the clinical efficacy of the nomogram. Conclusions: We developed a nomogram that enables early prediction of non-transplant FHR MM patients. Younger age at onset, LDH ≥ 220 U/L, an A + C pattern of M-protein decline, and induction therapy efficacy not reaching VGPR are more likely to be FHR MM patients. Patients who do not undergo maintenance therapy are prone to early progression or relapse.
- 9 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 145
Open AccessEarly Identification of the Non-Transplanted Functional High-Risk Multiple Myeloma: Insights from a Predictive Nomogram
Background: Patients with multiple myeloma (MM) who have a suboptimal response to induction therapy or early relapse are classified as functional high-risk (FHR) patients and have been shown to have a dismal prognosis. The aim of this study was to establish a predictive nomogram for patients with non-transplanted FHR MM. Materials and Methods: The group comprised 215 patients in our center between 1 January 2006 and 1 March 2024. To identify independent risk factors, univariate and multivariate logistic regression analyses were performed, and a nomogram was constructed to predict non-transplant FHR MM. To evaluate the nomogram’s predictive accuracy, we utilized bias-corrected AUC, calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC). Results: Multivariate logistic regression demonstrated that younger age at onset, a higher proportion of LDH (more than 220 U/L), pattern A + C of M protein decline patterns, a lower proportion of patients with induction treatment efficacy than VGPR, and those undergoing maintenance therapies were independent risk factors for patients with non-transplanted FHR MM. The AUC scores for the training and internal validation groups were 0.940 (95% CI 0.893–0.986) and 0.978 (95% CI 0.930–1.000). DCA and CIC curves were utilized to further verify the clinical efficacy of the nomogram. Conclusions: We developed a nomogram that enables early prediction of non-transplant FHR MM patients. Younger age at onset, LDH ≥ 220 U/L, an A + C pattern of M-protein decline, and induction therapy efficacy not reaching VGPR are more likely to be FHR MM patients. Patients who do not undergo maintenance therapy are prone to early progression or relapse.
- Open Access
- 6 April 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (8) , 9085-9096
Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
Background: The present study intended to establish a predictive nomogram for early relapse (ER) ( UNL, and response less than very good partial response (VGPR) after ASCT. The calibration curve showed good fitness between the nomogram predictions and the actual observations and the nomogram was further validated by a clinical decision curve. The nomogram's C‐index achieved 0.75 (95% CI, 0.70–0.80), which was higher than that of the Revised International Staging System (R‐ISS) (0.62), ISS (0.59), and Durie–Salmon (DS) staging system (0.52). The discrimination ability of the nomogram in the validation cohort was superior to that of the other staging systems (C‐index: 0.73 vs. R‐ISS (0.54), ISS (0.55), and DS staging system (0.53)). DCA showed the prediction nomogram adds much more clinical utility. Different scores of the nomogram draw a distinction of OS.Conclusion: The present nomogram could serve as a feasible and accurate prediction of ER in novel drug induction transplantation‐eligible MM patients, which could help modify the post‐ASCT strategy for patients at high risk of ER.
- 6 April 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (8) , 9085-9096
Open AccessPrognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
Background: The present study intended to establish a predictive nomogram for early relapse (ER) ( UNL, and response less than very good partial response (VGPR) after ASCT. The calibration curve showed good fitness between the nomogram predictions and the actual observations and the nomogram was further validated by a clinical decision curve. The nomogram's C‐index achieved 0.75 (95% CI, 0.70–0.80), which was higher than that of the Revised International Staging System (R‐ISS) (0.62), ISS (0.59), and Durie–Salmon (DS) staging system (0.52). The discrimination ability of the nomogram in the validation cohort was superior to that of the other staging systems (C‐index: 0.73 vs. R‐ISS (0.54), ISS (0.55), and DS staging system (0.53)). DCA showed the prediction nomogram adds much more clinical utility. Different scores of the nomogram draw a distinction of OS.Conclusion: The present nomogram could serve as a feasible and accurate prediction of ER in novel drug induction transplantation‐eligible MM patients, which could help modify the post‐ASCT strategy for patients at high risk of ER.
- Open Access
- 25 February 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (3) , 412
Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance
Background: Secondary primary malignancies (SPM) have attracted increasing attention with the application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in multiple myeloma (MM). Secondary acute lymphoblastic leukemia (sALL) has rarely been reported, and the clinical characteristics and prognosis of sALL have not been described in detail. Methods: We retrospectively enrolled 179 consecutive newly diagnosed multiple myeloma (NDMM) patients undergoing bortezomib-based induction regimens followed by upfront ASCT and maintenance therapy from December 2006 to April 2018 in our center. Results: The median follow-up interval was 69.1 months, and 12 patients (6.7%) developed sALL during maintenance therapy. The median time from the diagnosis of MM to the occurrence of sALL was 51.1 (31.7–91.5) months. All sALL patients received thalidomide as maintenance therapy before the onset of sALL, and the median duration of thalidomide maintenance was 39.5 (24–74) months. The cumulative incidence of sALL was 6.6% and 11.2% at 5 and 10 years after the diagnosis of MM, respectively. All sALL patients presented with a B-cell immunophenotype accompanied by myeloid antigen expression according to flow cytometry analysis, and the BCR/ABL fusion gene was all negative. Only one patient had evidence of active MM, and the other patients were in stable status at the time of the diagnosis of sALL. The prognosis of most sALL patients was very poor, and the median overall survival time was 11.9 (1.1–51.2) months since the diagnosis of sALL. Conclusions: sALL should be considered for MM patients who developed unexplained persistent cytopenia while on long-term thalidomide maintenance treatment, particularly if it has been more than 3 years. With the increasing availability of new drugs for MM, thalidomide may be recommended for no more than 3 years. Sequential allogeneic hematopoietic stem cell transplantation was considered as soon as possible after achieving remission in order to achieve a longer survival.
- 25 February 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (3) , 412
Open AccessClinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance
Background: Secondary primary malignancies (SPM) have attracted increasing attention with the application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in multiple myeloma (MM). Secondary acute lymphoblastic leukemia (sALL) has rarely been reported, and the clinical characteristics and prognosis of sALL have not been described in detail. Methods: We retrospectively enrolled 179 consecutive newly diagnosed multiple myeloma (NDMM) patients undergoing bortezomib-based induction regimens followed by upfront ASCT and maintenance therapy from December 2006 to April 2018 in our center. Results: The median follow-up interval was 69.1 months, and 12 patients (6.7%) developed sALL during maintenance therapy. The median time from the diagnosis of MM to the occurrence of sALL was 51.1 (31.7–91.5) months. All sALL patients received thalidomide as maintenance therapy before the onset of sALL, and the median duration of thalidomide maintenance was 39.5 (24–74) months. The cumulative incidence of sALL was 6.6% and 11.2% at 5 and 10 years after the diagnosis of MM, respectively. All sALL patients presented with a B-cell immunophenotype accompanied by myeloid antigen expression according to flow cytometry analysis, and the BCR/ABL fusion gene was all negative. Only one patient had evidence of active MM, and the other patients were in stable status at the time of the diagnosis of sALL. The prognosis of most sALL patients was very poor, and the median overall survival time was 11.9 (1.1–51.2) months since the diagnosis of sALL. Conclusions: sALL should be considered for MM patients who developed unexplained persistent cytopenia while on long-term thalidomide maintenance treatment, particularly if it has been more than 3 years. With the increasing availability of new drugs for MM, thalidomide may be recommended for no more than 3 years. Sequential allogeneic hematopoietic stem cell transplantation was considered as soon as possible after achieving remission in order to achieve a longer survival.
- 10 February 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (4) , 1110-1116
Clinical observation and dermoscopy evaluation of fractional CO2 laser combined with topical tranexamic acid in melasma treatments
Background: Melasma is an acquired refractory pigmentary disorder, which is a skin disease that predominantly affects females. This investigation aims to assess the efficacy of a low‐power fractional CO2 laser combined with tranexamic acid (TXA) for melasma topical treatment with MASI and dermoscopy.Materials and Methods: A randomized comparative split‐face study was performed. Each treatment interval was 3 weeks with four times in total. At the same time, we applied TXA solution twice a day. Assessments were made by the MASI score of the melasma area severity index, and the dermoscopy performance was collected and analyzed.Results: After treatments, the patient MASI score decreased significantly. Compared with the baseline, the MASI score was significantly lower than that of control group (P < .05), and the decrease ratio was higher than that of controls. Dermoscopy examination results verified that all lesions performed reticuloglobular pattern, granular, or punctate, with no structural pigmentation and obvious capillary dilation. After comprehensive treatments, the pigmentation area displayed lighter chroma, the follicle pore uniformity was completely improved, and the capillary dilation was significantly reduced.Conclusions: Low‐power fractional CO2 laser combined with topical TXA solution is a comparatively effective and safe method for melasma treatment. TXA could reduce the dilation of blood vessels.
- 10 February 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (4) , 1110-1116
Clinical observation and dermoscopy evaluation of fractional CO2 laser combined with topical tranexamic acid in melasma treatments
Background: Melasma is an acquired refractory pigmentary disorder, which is a skin disease that predominantly affects females. This investigation aims to assess the efficacy of a low‐power fractional CO2 laser combined with tranexamic acid (TXA) for melasma topical treatment with MASI and dermoscopy.Materials and Methods: A randomized comparative split‐face study was performed. Each treatment interval was 3 weeks with four times in total. At the same time, we applied TXA solution twice a day. Assessments were made by the MASI score of the melasma area severity index, and the dermoscopy performance was collected and analyzed.Results: After treatments, the patient MASI score decreased significantly. Compared with the baseline, the MASI score was significantly lower than that of control group (P < .05), and the decrease ratio was higher than that of controls. Dermoscopy examination results verified that all lesions performed reticuloglobular pattern, granular, or punctate, with no structural pigmentation and obvious capillary dilation. After comprehensive treatments, the pigmentation area displayed lighter chroma, the follicle pore uniformity was completely improved, and the capillary dilation was significantly reduced.Conclusions: Low‐power fractional CO2 laser combined with topical TXA solution is a comparatively effective and safe method for melasma treatment. TXA could reduce the dilation of blood vessels.